Jun. 16 at 10:01 PM
$GALT At this stage in the game, that seemed to be a very odd call in terms of the timing and content. Puzzling to say the least. Who was the target audience of this call? Certainly not retail investors, certainly not the clinicians and medical experts (other venues for that). Wall street analysts and investment firms - no significant new data was released and without new info why would they care at this point with the company on the verge of a partnership or buyout? All the real action should be taking place behind the scenes and confidentially with partners, prospective buyers, the FDA and other relevant stakeholders. The only thing I can surmise is that they are grasping at straws or they want a full disclosure prior to an announcement. Others please chime in here as I'm a bit perplexed.
